FDA approves Dr Reddy’s Vascepa generic

Indian drugmaker Dr Reddy’s has won approval to launch just the second generic version of heart drug Vascepa (icosapent ethyl), in another blow for Amarin.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Judge allows Dr Reddy’s to add antitrust claims in Indivior dispute

25 August 2020 A district judge has given India-based Dr Reddy’s the greenlight to move forward with its antitrust counterclaims against Indivior.

Big Pharma

Amarin vows to challenge Vascepa patent ruling

4 September 2020 Amarin has announced it will seek an en banc rehearing of a decision at the US Court of Appeals for the Federal Circuit that failed to revive its patents on heart medicine Vascepa.

Americas

BMS and Dr Reddy’s settle Revlimid suit with generics licence

22 September 2020 Bristol Myers Squibb and Celgene have settled their patent litigation with Dr Reddy’s over a generic version of cancer drug Revlimid.

More on this story

Americas

Judge allows Dr Reddy’s to add antitrust claims in Indivior dispute

25 August 2020 A district judge has given India-based Dr Reddy’s the greenlight to move forward with its antitrust counterclaims against Indivior.

Big Pharma

Amarin vows to challenge Vascepa patent ruling

4 September 2020 Amarin has announced it will seek an en banc rehearing of a decision at the US Court of Appeals for the Federal Circuit that failed to revive its patents on heart medicine Vascepa.

Americas

BMS and Dr Reddy’s settle Revlimid suit with generics licence

22 September 2020 Bristol Myers Squibb and Celgene have settled their patent litigation with Dr Reddy’s over a generic version of cancer drug Revlimid.

More on this story

Americas

Judge allows Dr Reddy’s to add antitrust claims in Indivior dispute

25 August 2020 A district judge has given India-based Dr Reddy’s the greenlight to move forward with its antitrust counterclaims against Indivior.

Big Pharma

Amarin vows to challenge Vascepa patent ruling

4 September 2020 Amarin has announced it will seek an en banc rehearing of a decision at the US Court of Appeals for the Federal Circuit that failed to revive its patents on heart medicine Vascepa.

Americas

BMS and Dr Reddy’s settle Revlimid suit with generics licence

22 September 2020 Bristol Myers Squibb and Celgene have settled their patent litigation with Dr Reddy’s over a generic version of cancer drug Revlimid.

More features

President Trump 2.0: Five major areas to watch

Startup CFO’s betrayal is a lesson in preparing for the worst

Sandoz lands reduced antitrust award of $70m

New president’s to-do list: Patent bills, non-competes, USPTO director?

Sanofi subsidiary fends off $450m trade secrets case

Regulatory expert joins White & Case

Teva faces $500m fine for antitrust breaches over MS drug

UK Budget: A missed opportunity?

FDA approves Dr Reddy’s Vascepa generic

More on this story

Editor's picks

Editor's picks

More on this story

More on this story

More features